- Record: found
- Abstract: found
- Article: not found
Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
Celina García-García
1 ,
Yasir H Ibrahim ,
Violeta Serra ,
Maria Teresa Calvo ,
Marta Guzmán ,
Judit Grueso ,
Claudia Aura ,
José Pérez ,
Katti Jessen ,
Yi Liu ,
Christian Rommel ,
Josep Tabernero ,
José Baselga ,
Maurizio Scaltriti
May 01 2012
Read this article at
ScienceOpenPublisherPubMed
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
- oa repository (via page says license)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The PI3K/Akt/mTOR pathway is an attractive target in HER2-positive breast cancer that is refractory to anti-HER2 therapy. The hypothesis is that the suppression of this pathway results in sensitization to anti-HER2 agents. However, this combinatorial strategy has not been comprehensively tested in models of trastuzumab and lapatinib resistance.